WuXi AppTec Delivers Best Ever Q2 Performance

WuXi AppTec Delivers Best Ever Q2 Performance

More than half of 2025 has passed. Despite a series of blockbuster deals in the innovative drug sector attracting global attention, the fundamentals of investment and financing remain unfavorable.

According to statistics from Artery Network, in the first half of 2025, both the number and amount of financing events in the global healthcare industry continued to decline, failing to maintain the stabilization trend seen in 2024. Over a longer period, although market transaction activity remains high, the decrease in amounts has pushed average deal sizes to historic lows, with investment institutions increasingly favoring targets with greater certainty.

Amidst multiple external challenges, WuXi AppTec, a CRDMO company, took only one quarter to move from maintaining its full-year performance guidance to raising it.

Yesterday, WuXi AppTec released its results for the first half of 2025. On a large base, its revenue and adjusted non-IFRS net profit attributable to shareholders both achieved double-digit growth, exceeding 20% and 40% respectively. Even more impressively, WuXi AppTec’s backlog orders hit a new high, indicating that its growth trajectory is far from peaking.

Such numbers are remarkable even within WuXi AppTec’s traditionally strong performance records. Looking separately at Q1 and Q2, WuXi AppTec’s continuing operations revenue for Q2 reached 11.14 billion RMB, a year-over-year increase of over 24%. This marks the first time the company has surpassed 10 billion RMB in revenue in Q2 alone.

Considering WuXi AppTec’s usual steady revenue climb from Q1 through Q4, it is expected that Q3 and Q4 will deliver even stronger performances, with quarterly revenue likely exceeding 10 billion RMB. It is no surprise that the company raised its full-year guidance—not only projecting continuing operations revenue to return to double-digit growth with an upgraded growth rate from 10–15% to 13–17%, but also increasing overall revenue guidance from 41.5–43 billion RMB to 42.5–43.5 billion RMB. Free cash flow forecasts were also raised from 4–5 billion RMB to 5–6 billion RMB.

From WuXi AppTec’s impressive half-year results and raised guidance, we can boldly draw three conclusions:

1. Industry cycles and regional fluctuations are inevitable, but regardless of external changes, demand for innovative pharmaceutical collaboration only grows. WuXi AppTec remains at the forefront of understanding and meeting customer needs globally.
2. The advantages of the integrated CRDMO model are indisputable. Whether for small molecules or new molecular entities, WuXi AppTec’s pipeline is continuously replenished, with backlog orders growing on a large base, demonstrating strong certainty.
3. It is crucial not to overlook that the efficient flow of the large CRDMO pipeline is underpinned by meticulous management and strong execution capabilities. This has likely become a new source of certainty for WuXi AppTec and a competitive edge that is difficult to replicate.

The intrinsic value of WuXi AppTec may still be underestimated.

The Best Q2 in History

This first half of the year saw frequent large transactions between major pharmaceutical companies and small or emerging biotech firms, such as Sihuan Pharmaceutical with Pfizer, and HaploMed with AstraZeneca. This vibrant scene reflects an unchanged major trend in the innovative drug field: demand for innovative collaboration continues to rise, but both large and small pharma companies face their own pressures.

On one hand, small and emerging biotech companies face funding difficulties. “Currently, about 40% of listed biotech companies have less than one year of cash flow,” said Ashwin Singhania, EY’s Life Sciences Strategy Lead, during a recent report call. “This is due to a very tough financing environment.”

On the other hand, large pharma companies also face challenges. EY’s report shows that the top 20 pharmaceutical companies hold a huge cash reserve estimated at 1.27 trillion USD at the start of this year. However, with patents on several best-selling drugs expiring soon, these companies will face a revenue growth gap exceeding 300 billion USD by 2028.

Science and technology continue to advance rapidly. Emerging companies need funding, and large pharmaceutical companies need to expand their innovation pipelines. Although their goals differ, both require efficient, high-quality, and cost-effective R&D and manufacturing services to strongly push their pipelines forward.

WuXi AppTec serves thousands of pharmaceutical companies, and its solid performance proves its deep insight into and ability to satisfy the needs of both large and small pharma clients. According to its half-year report, WuXi AppTec’s continuing operations revenue exceeded 20.4 billion RMB in H1 2025, up 24.2% year-over-year; adjusted non-IFRS net profit reached 6.31 billion RMB, up 44.4% year-over-year.

Analyzing in detail, this high growth is not driven by any single market or sector but is the combined result of projects across global regions and various pipeline categories.

According to WuXi AppTec’s report, business from the U.S., Europe, Japan, South Korea, and other Asia-Pacific regions all continued to grow. In H1, revenue from the U.S. reached 14.03 billion RMB, maintaining a high growth rate of over 38% year-over-year on a large base. Europe’s revenue growth exceeded 9%, working synergistically with China, Japan, South Korea, and other Asia-Pacific markets.

Additionally, whether traditional small molecules or the currently hot new molecular TIDES (peptides and oligonucleotides), WuXi AppTec has secured a large number of orders from pharmaceutical companies. In H1 2025, WuXi Chemistry, the company’s small molecule and new molecular CRDMO platform, achieved revenue of 16.3 billion RMB, up 33.5% year-over-year. Among these, the new molecular business was not only outstanding but also injected further market imagination—as capacity expands quarter by quarter, WuXi TIDES revenue reached 5.03 billion RMB in H1, soaring 141.6% year-over-year, with backlog orders growing nearly 50% year-over-year.

Whether revenue, net profit, or backlog orders, these increases are solid and tangible—the company’s cash flow growth trend matches its net profit growth closely. According to disclosed data, WuXi AppTec’s operating cash flow reached 7.07 billion RMB in H1, up 49.1% year-over-year.

Taken together, this shows WuXi AppTec has not sacrificed profit or cash flow for growth; its high growth is healthy and sustainable.

Proven Model, Strong Execution

So, how was this best-ever and still “upward momentum” Q2 achieved?

WuXi AppTec’s CRDMO business model is its well-known “success formula.” Simply put, this integrated, end-to-end model provides comprehensive services spanning new drug early discovery (R), development (D), and manufacturing (M), covering various types of innovative molecules.

Focusing on pharma companies’ specific needs, this integrated model is especially valuable for small biotech companies that often cannot build their own full industry-chain R&D and manufacturing facilities and face high risks if any single project fails. CRDMO’s comprehensive support helps them use funds efficiently and accelerate pipeline advancement to key value-creating milestones. Large pharma companies, expanding pipelines through acquisitions and drug licensing, also rely on WuXi AppTec’s CRDMO to optimize new drug development and capital efficiency.

Previously, Morgan Stanley interviewed leaders from 108 global pharma companies and summarized seven key CXO capabilities, ranking “integrated, end-to-end” as number one.

Because it meets the diverse needs of all kinds of pharma companies, molecule types, and new drug development stages, the CRDMO model provides WuXi AppTec with a solid long-term growth foundation: molecules discovered upstream flow continuously downstream, expanding flow volume, identifying and capturing potential blockbuster molecules early, and pushing them steadily to later stages, thereby significantly growing revenue, profit, and cash flow simultaneously.

Since WuXi AppTec introduced the CRDMO model several years ago, this advantage has been clearly reflected quarter after quarter in financial reports, including the current one.

In the first half of 2025, despite a relatively weak early discovery market (R phase), WuXi Biology continuously attracted new customers, adding over 20% new clients and achieving revenue growth of 7.1% year-over-year.

Development and manufacturing (D&M) growth was more pronounced. In H1 2025, WuXi supported 158 small molecules moving from R to D phase, with over 3,300 small molecules supported at the D phase, up 3% year-over-year. Commercial stage small molecules grew even more, up 13%. H1 revenue for small molecule D&M business reached 8.68 billion RMB, up 17.5% year-over-year.

Notably, WuXi AppTec’s meticulous management and strong execution are critical to enabling so many pharma companies to sequentially use its services. The continuous increase in adjusted non-IFRS net profit attributable to shareholders also indirectly reflects improved operational efficiency.

While the model may be emulated, not all CXOs can deliver strong capabilities, efficiency, and quality across every stage. This has become WuXi AppTec’s “hard power,” its “know-how” that outsiders cannot replicate.

Precise insight into and grasp of customer needs, a strong integrated CRDMO business model, meticulous management, and powerful execution—these three major advantages provide WuXi AppTec’s future development with solid “certainty.”

When so much certainty is compounded over time, we may witness a company’s “moat” rapidly build, its growth curve soar, making the leap from excellence to greatness and joining the ranks of the strongest—an occurrence seen many times throughout history.

Let us wait and see.